Delcath Systems(NASDAQ) DCTH

Delcath Systems, Inc. helps doctors treat cancer that has spread to the liver. Its technology delivers high-dose medicine directly to the organ while protecting the rest of the body. This approach aims to reduce side effects for patients with specific types of liver cancer.

Delivering Medicine Where It Matters

• HEPZATO KIT: Combined drug and device system that delivers chemotherapy directly to the liver; treats eye cancer that has spread.
• CHEMOSAT: Stand-alone medical device version of the delivery system approved for sale in Europe.

Trials and Commercial Expansion

• Started first commercial use of HEPZATO KIT for eye cancer that spread in January 2024.
• Received European Medical Device Regulation certification for the CHEMOSAT system on Feb. 28, 2022.
• Assumed direct responsibility for European sales and marketing of CHEMOSAT on March 1, 2022.
• Received clearance for a Phase 2 trial for liver-dominant colorectal cancer in December 2024.
• Initiated patient enrollment for a Phase 2 breast cancer clinical trial in the third quarter of 2026.

What Makes Delcath Different?

The company holds six orphan drug designations, which are special statuses given to treatments for rare diseases. Delcath manages supply chain risks by stockpiling inventory and using multiple suppliers for its essential product components.

Revenue and Research Highlights

• Total revenue was $29.1 million for the three months ended June 30, 2026.
• Total revenue reached $54.1 million for the six months ended June 30, 2026.
• Research and development expenses reached $20.2 million for the six-month period ended June 30, 2026.
• Combined cash and short-term investments totaled $95.9 million as of June 30, 2026.

Evolution Into a Commercial Firm

Delcath has evolved from a clinical research organization into a commercial oncology company with active sales operations. Its expansion into new clinical trials for colorectal and breast cancers reflects a strategy to treat broader patient populations.